iSpecimen
Logotype for iSpecimen Inc

iSpecimen (ISPC) investor relations material

iSpecimen Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for iSpecimen Inc
Q3 2026 earnings summary17 Nov, 2026

Executive summary

  • Q3 revenue rose 129% YoY to $244,034, while nine-month revenue fell 71% to $551,983 as specimen volume declined; nine-month net loss widened 7% to $5.85M.

  • Available cash was $5.56M at September 30, 2026, and management reported substantial doubt about continuing as a going concern for one year after issuance.

Financial highlights

  • Q3 operating loss was $2.20M vs. $2.83M YoY; net loss was $2.21M vs. $2.78M, and basic and diluted EPS was $(1.03) vs. $(19.05), split-adjusted.

  • Nine-month operating loss was $6.10M vs. $6.29M YoY; net loss was $5.85M vs. $5.49M, and basic and diluted EPS was $(4.49) vs. $(61.54), split-adjusted.

  • Q3 revenue increased 129% to $244,034; nine-month revenue declined 71% to $551,983, with specimen volume down 61% to 1,977 and average selling price down 24% to ~$279.

  • Nine-month operating expenses fell 19% to $6.65M; sales and marketing increased 99% to $3.47M, while technology fell 48% to $841,426.

  • Cash was $5.56M, working capital $870,936, total assets $9.70M, and stockholders’ equity $4.07M at September 30, 2026.

Outlook and guidance

  • Plans include driving revenue through revenue-enhancement initiatives, reducing and managing expenses, deferring projects and capital expenditures, and eliminating future operating costs; success is not assured.

  • Commercial priorities include account-based selling, an outbound sales team, closer sales-marketing coordination, and faster quote conversion; next-day quotes had a 44% quote-to-order conversion ratio through Q3 2026.

  • Management intends to use existing cash for supply-network growth, increased sales and marketing presence, operational scaling, working capital, and general corporate purposes.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next iSpecimen earnings date

Logotype for iSpecimen Inc
Q4 20269 Apr, 2027
iSpecimen
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next iSpecimen earnings date

Logotype for iSpecimen Inc
Q4 20269 Apr, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

iSpecimen Inc. is a technology-driven company that connects researchers with human biospecimens for medical research and development. Through its proprietary online marketplace, the company facilitates the procurement of biological samples, including blood, tissue, and other biofluids, from a global network of healthcare providers. iSpecimen serves pharmaceutical companies, biotechnology firms, academic institutions, and government organizations involved in drug discovery, diagnostics, and precision medicine. iSpecimen Inc. is headquartered in Lexington, Massachusetts, and its shares are listed on the NASDAQ.